Physician profile

John M Lee

Interventional Cardiology · Plano, TX

NPI 1679764948

$9,659.27

in general payments reported to CMS, 2019-2025

40 companies · $1,488 in 2025

The $1,488 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,787.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $2,780.99 2019-2025 Avvigo Guidance System, General - Balloon Catheters
Amgen INC. $892.41 2019-2025 Repatha, Repatha
Abiomed $817.34 2021-2025 Impella
Novartis Pharmaceuticals Corporation $590.20 2019-2025
Medtronic, INC. $579.17 2023-2025 Onyx Frontier, Linq II, Micra
Abbott Laboratories $509.20 2019-2025 Thoratec Heartmate 3 Lvas Implant Kit, Dragonfly Opstar, Jot Dx
Pfizer INC. $351.80 2022-2025
Astrazeneca Pharmaceuticals LP $305.90 2019-2024 Farxiga, Brilinta, Andexxa
Merck Sharp & Dohme LLC $273.44 2021-2025 Verquvo
E.R. Squibb & Sons, L.L.C. $271.78 2019-2025 Camzyos, Eliquis
Shockwave Medical, INC $264.47 2019-2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Janssen Pharmaceuticals, INC $232.41 2019-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $193.40 2019-2025 Lifevest
Biotronik INC. $156.90 2022
Kiniksa Pharmaceuticals, LTD. $149.98 2022-2023 Arcalyst
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Heartflow, INC. $124.95 2022-2023 Ffrct
Cardiva Medical, INC. $109.33 2019-2022
Medtronic Vascular, INC. $108.69 2019
Boehringer Ingelheim Pharmaceuticals, INC. $107.89 2019-2024 Jardiance
Astellas Pharma US INC $97.60 2019-2021
Novo Nordisk INC $96.32 2024-2025 Ozempic, Rybelsus
Philips North America LLC $84.00 2019-2025 Extended Holter
Kestra Medical Technology Services, INC. $68.21 2025 Assure Wcd
Alnylam Pharmaceuticals INC. $49.71 2022-2023 Onpattro
Irhythm Technologies, INC. $48.69 2023 Zio Xt Patch
Lexicon Pharmaceuticals, INC. $47.78 2024
Davol INC. $45.68 2025 Arista
Medicomp INC $43.00 2024 Telepatch Cardiac Monitor
Atricure, INC. $31.78 2024
Recor Medical INC $29.17 2025 Paradise Ultrasound Renal Denervation System
Glaxosmithkline, LLC. $26.47 2025 Arexvy
Becton, Dickinson and Company $25.85 2024 Rotarexs 6 F X 135 Cm
Kiniksa Pharmaceuticals International, Plc $22.59 2024 Arcalyst
Cvrx, INC. $21.46 2024 Barostim Neo System
Cordis US Corp. $18.21 2024 Rain Sheath
Edwards Lifesciences Corporation $17.75 2019
Esperion Therapeutics, INC. $17.13 2022
Regeneron Healthcare Solutions, INC. $16.95 2019
Scpharmaceuticals INC. $16.26 2025
Chiesi USA, INC. $14.41 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John M Lee

$9,659.27

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $1,488 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/553148/john-m-lee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.